Patients with DICER1 predisposition syndrome have an increased risk to develop pleuropulmonary blastoma, cystic nephroma, embryonal rhabdomyosarcoma, and several other rare tumor entities. In this study, we identified 22 primary intracranial sarcomas, including 18 in pediatric patients, with a distinct methylation signature detected by array-based DNAmethylation profiling. In addition, two uterine rhabdomyosarcomas sharing identical features were identified. Gene panel sequencing of the 22 intracranial sarcomas revealed the almost unifying feature of DICER1 hotspot mutations (21/22; 95%) and a high frequency of co-occurring TP53 mutations (12/22; 55%). In addition, 17/22 (77%) sarcomas exhibited alterations in the mitogen-activated protein kinase pathway, most frequently affecting the mutational hotspots of KRAS (8/22; 36%) and mutations or deletions of NF1 (7/22; 32%), followed by mutations of FGFR4 (2/22; 9%), NRAS (2/22; 9%), and amplification of EGFR (1/22; 5%). A germline DICER1 mutation was detected in two of five cases with constitutional DNA available. Notably, none of the patients showed evidence of a cancer-related syndrome at the time of diagnosis. In contrast to the genetic findings, the morphological features of these tumors were less distinctive, although rhabdomyoblasts or rhabdomyoblastlike cells could retrospectively be detected in all cases. The identified combination of genetic events indicates a relationship between the intracranial tumors analyzed and DICER1 predisposition syndrome-associated sarcomas such as embryonal rhabdomyosarcoma or the recently described group of anaplastic sarcomas of the kidney. However, the intracranial tumors in our series were initially interpreted to represent various tumor types, but rhabdomyosarcoma was not among the typical differential diagnoses considered. Given the rarity of intracranial sarcomas, this molecularly clearly defined group comprises a considerable fraction thereof. We therefore propose the designation "spindle cell sarcoma with rhabdomyosarcoma-like features, DICER1 mutant" for this intriguing group.
Introduction
Intracranial mesenchymal tumors mostly affect the leptomeningeal coverings of the CNS. The predominant tumors are meningioma and hemangiopericytoma/solitary fibrous tumor, both of which are well-defined tumor entities [18] . However, less commonly a great variety of other sarcomas can manifest either primarily or secondarily in the brain. More often, malignant gliomas undergo mesenchymal transition and subsequently are diagnosed as gliosarcoma [18] . Mesenchymal brain tumors predominantly arise in adult patients. However, they rarely also affect children and, in this setting, they are often associated with syndromic disorders [16, 19, 26] . In general, pediatric intracranial mesenchymal tumors, not clearly falling into the group of meningioma or hemangiopericytoma/solitary fibrous tumor, pose a diagnostic challenge.
Recent omic-based approaches have demonstrated great promise for the classification of tumors. Methylation analysis has proven of high reproducibility allowing precise classification of known and identification of novel brain tumor entities [28, 32, 33] . The methylation-based concept relies on the hypothesis that promoter methylation patterns correspond to discrete time points in developing cells (i.e., putative cells of origin) and that methylation patterns are fairly stable throughout tumor progression [23] . This concept has shown to be very successful for the development of a global brain tumor classifier [1] . Methylation-based classification is currently expanded to include sarcomas and, for instance, has shown great power in distinguishing mesenchymal small blue round cell tumors mimicking Ewing sarcoma [14] .
We here report on a significant group of intracranial pediatric sarcomas, which histologically exhibit considerable heterogeneity but by molecular omic analyses emerge as a homogenous entity sharing a characteristic methylation profile and a set of highly recurrent mutations.
Materials and methods

Sample selection and DNA extraction
We performed unsupervised clustering of methylation data generated from primary intracranial tumors and peripheral sarcomas analyzed at the German Cancer Research Center (DKFZ) and focused on clusters not matching those of previously established methylation groups [1, 14, 15] . Additional samples for further methylation testing were supplied by the Peruvian National Cancer Center and its cooperating institutes. Source material for DNA extraction was formalinfixed and paraffin-embedded (FFPE) tumor tissue. Representative tumor tissue with highest available tumor content was chosen for DNA extraction. The Maxwell ® 16 FFPE Plus LEV DNA Kit or the Maxwell ® 16 Tissue DNA Purification Kit (for frozen tissue) was applied on the automated Maxwell device (Promega, Madison, WI, USA) according to the manufacturer's instructions. All tumor DNAs had a total amount of > 100 ng and were suitable for the array-based DNA-methylation analysis. Germline information was available from five patients that had been enrolled in the MNP2.0, PTT2.0 or INFORM trial. Tissue collection, processing, and data collection were in compliance with local ethics regulation and approval.
Genome-wide DNA-methylation data generation and pre-processing All tumors were subjected to Illumina Infinium HumanMethylation450 (450 k) BeadChip or the successor EPIC/850k BeadChip (Illumina, San Diego, USA) analysis at the Genomics and Proteomics Core Facility of the German Cancer Research Center (DKFZ) Heidelberg or at the Institute for Neuropathology at the University Medical Center Hamburg-Eppendorf. DNA-methylation data were normalized by performing background correction and dye bias correction (shifting of negative control probe mean intensity to zero and scaling of normalization control probe mean intensity to 20,000, respectively). Probes targeting sex chromosomes, probes containing multiple single nucleotide polymorphisms, and those that could not be uniquely mapped were removed. Probes from the EPIC array were excluded if the predecessor Illumina Infinium 450 k BeadChip did not cover them, thereby making data generated by both 450k and EPIC feasible for subsequent analyses. In total, 438,370 probes were kept for analysis.
Unsupervised clustering, t-SNE analysis, and cumulative copy number plotting
For unsupervised hierarchical clustering, we selected 10,000 probes that showed the highest median absolute deviation (MAD) across the beta values. Samples were hierarchically clustered using the Euclidean distance and Ward's linkage method. Methylation probes were reordered by hierarchical clustering using Euclidean distance and complete linkage. The unscaled methylation levels were shown in a heat map from unmethylated state (blue color) to methylated state (red color). For unsupervised 2D representation of pairwise sample correlations, dimensionality reduction by t-distributed stochastic neighbor embedding (t-SNE) was performed using the 10,000 most variable probes, a perplexity of 20 and 2500 iterations. Novel methylation groups were tested for stability by varying the number of the most variable probes. Copy number assessment was done based on methylation array data using the R-package conumee.
Gene panel next-generation sequencing
A customized SureSelect XT technology (Agilent) panel covering the coding regions of 130 genes was applied. Library preparation, quality control, sequencing on a NextSeq sequencer (Illumina), and data processing were performed as previously described [27] . Reads were aligned against the reference genome hg19. Gene panel-sequencing data were automatically annotated using ANNOVAR software [37] . Synonymous and stop-loss variants, variants with a frequency exceeding 1% in the healthy population as well as variants described as known polymorphisms in the single nucleotide polymorphism database were not considered.
Immunohistochemistry
A representative block was chosen for immunohistochemistry. 4-µm paraffin sections were dried at 80 °C for 15 min and stained on a Ventana BenchMark XT immunostainer (Ventana Medical Systems, Tucson, AZ, USA) using standard techniques. The following antibodies were applied: α-smooth muscle actin (Dako, Carpinteria, CA, USA, mouse monoclonal, clone 1A4), desmin (Dako, mouse monoclonal, clone D33), and myogenin (Cell Marque, Rocklin, CA, USA, mouse monoclonal, clone F5D).
Results
Distinct methylation signature in a significant proportion of CNS sarcomas NOS
We identified 11 intracranial tumors forming a previously undetected methylation group. These tumors had previously been diagnosed as CNS sarcoma NOS (n = 4), intracranial malignant tumor NOS (n = 2), and five cases each diagnosed as glioblastoma, gliosarcoma, extraskeletal mesenchymal chondrosarcoma, primitive neuroectodermal tumor (PNET), and embryonal rhabdomyosarcoma. Interestingly, two embryonal rhabdomyosarcomas of the uterus also fell into this methylation group. Subsequent methylation analysis of 11 pediatric intracranial sarcomas NOS from Peru demonstrated similarity with the same novel methylation group.
Next, we selected from our pool of tumors 26 morphologically and epigenetically defined entities to be distinguished from our novel group. The 26 entities covered the spectrum of differential diagnoses to the initial diagnosis of our study cohort, among them DICER1-related tumors such as pineoblastoma and medulloepithelioma of the eye. The defined entities and the number of tumors included are provided in Suppl. Table 1 (Online Resource 1).
Unsupervised clustering (Fig. 1a) and t-SNE analysis (Fig. 1b ) of these 26 entities together with our novel group confirmed characteristic and distinctive methylation patterns.
Clinical characteristics and morphological features
All cases were located intracranially apart from the two uterine tumors. With two exceptions in the cerebellopontine angle and the cerebellum the intracranial tumors were located supratentorially (20/22) . The age distribution of the 22 intracranial cases ranged from 0 to 76 years with a median age of 6 years. The gender distribution was almost equal with a female (n = 12) to male (n = 10) ratio of 1.2:1. Basic clinical information of the study cases is summarized in Table 1 .
Histologic features could be assessed in 20/22 intracranial cases (Fig. 2) . The tumor cells appeared mostly spindle shaped and were surrounded by thin, focally coarse, argyrophilic fibers. The predominant tumor growth was patternless in 15 cases (15/20; 75%) and fascicular in five cases (5/20; 25%). Overall, the cellularity was variable in most cases with a patternless architecture, but markedly increased in cases with a predominant fascicular growth pattern. The mitotic activity was brisk in all cases. Atypical mitotic figures were observed in 14 cases (14/20; 70%). Focal areas with coagulative necrosis were present in 13 cases (13/20; 65%). Rhabdomyoblasts or rhabdomyoblast-like cells were observed in all cases. These cells were most obvious in areas with lower cellularity, but single cells reminiscent of rhabdomyoblasts could also be identified in highly cellular tumors. Cartilaginous differentiation was seen only in one primary intracranial case (1/20; 5%), which presented a highly variable morphology (Suppl. Figure 1 ; Online Resource 2). However, cartilaginous nodules were present in one of the two uterine cases.
The immunophenotype could be assessed in 17/22 intracranial cases (Fig. 3) . Smooth muscle actin was detected in all 17 cases, desmin in 14 cases (14/17; 82%), and myogenin was positive in five cases (5/17; 29%). However, myogeninpositive cells were sometimes sparsely scattered. Other lineage markers such as CD34, S100, EMA, or pan-cytokeratin AE1/3, where available, were consistently negative. Histologic features and immunophenotypes are listed in Suppl. 
Highly recurrent DICER1 mutations concomitant with mitogen-activated protein kinase (MAPK) pathway and TP53 mutations
We next investigated the cohort, including two uterine rhabdomyosarcomas, for molecular alterations by DNA sequencing (Fig. 4) and copy number profiling (Fig. 5) . Next-generation panel-sequencing revealed 29 DICER1 mutations in 23 tumors. 23 missense mutations were located in mutational hotspots within exons 24 and 25, both coding for the RNase IIIb domain. In addition, six cases had a second mutation, four of which resulted in a premature stop codon, one in a frameshift mutation, and one in an additional missense mutation. We were able to further examine germline DNA from a total of five patients, two of them with a second DICER1 nonsense mutation. These two cases contained a somatic hotspot missense mutation and a germline nonsense mutation. Seven of 22 SCS-RMSlike-DICER1 exhibited loss on 14q encompassing the DICER1 locus compatible with loss of portions of one parental chromosome. Five of these exhibited a mutant allele frequency of 60% or more further supporting the presence of biallelic inactivation of DICER1. A summary copy number plot is shown in Fig. 5 .
We additionally detected recurrent mutations in the MAPK pathway. In detail, KRAS hotspot mutations were seen in eight, NF1 mutations in seven with one case showing a homozygous deletion, NRAS hotspot mutations in two, RAF1 and FGFR4 mutations in two each, and EGFR amplification in one of the tumors. Four tumors exhibited two MAPK pathway mutations resulting in 17/22 tumors (77%) being affected in this pathway.
Furthermore, four cases harbored mutations either in SMO (2/22; 9%) or in SUFU (2/22; 9%), both known for their pivotal role in activating the hedgehog pathway. Three cases with a hedgehog pathway mutation also had mutations in the MAPK pathway.
TP53 mutations were found in 13/24 (54%) cases. Unfortunately, germline information were unavailable in these TP53 mutant cases.
All variants and the respective distributions are depicted in Fig. 4 . Molecular data are provided in Suppl. Table 3 (Online Resource 4).
Discussion
We here report a series of 22 intracranial sarcomas in predominantly pediatric patients, which closely resemble embryonal rhabdomyosarcomas with DICER1 mutations in terms of a distinct methylation signature and the presence of DICER1 mutations [2, 3, 6, 7, 10] . We propose the designation "spindle cell sarcoma with rhabdomyosarcoma-like features, DICER1 mutant" (SCSRMSlike-DICER1) for this group. The methylation signature of SCS-RMSlike-DICER1 was distinct compared to 26 tumor subtypes with established methylation groups representing differential diagnoses to the initial diagnoses allotted to the tumors in our series. Both, unsupervised cluster and t-SNE analyses clearly demonstrate a strict separation of SCS-RMSlike-DICER1 from the other tumors. The combination of a unique methylation signature, a defining mutation in more than 95% of cases, and the predominant occurrence within the pediatric age group strongly argues that SCSRMSlike-DICER1 constitutes a distinct sarcoma entity.
In contrast to the unequivocal genetic features, the morphology of SCS-RMSlike-DICER1 is highly variable. For this reason, the tumors in our series initially had been diagnosed as sarcoma NOS, mesenchymal chondrosarcoma, glioblastoma, gliosarcoma or PNET. This is not surprising, since the tumor architecture in these tumors is highly diverse and the tumor cell appearance quite heterogeneous, although the spindle cell morphology predominates. High cellularity, brisk mitotic activity, and presence of intermingled rhabdomyoblasts or rhabdomyoblast-like cells is common to all SCS-RMSlike-DICER1. While these cells in some instances focally predominate or are quite obvious, they may be infrequently encountered in most of the cases. Approximately 30% of SCS-RMSlike-DICER1 exhibited focal expression of myogenin.
Previous studies have reported some cases of intracranial rhabdomyosarcomas [8, 20, 24, 25, 34] , most of them localized in the cerebellum. This contrasts with the supratentorial localization of the tumors in our series. While this may indicate separate groups, the DICER1 status of cerebellar rhabdomyosarcomas has not been determined. The two cases in our SCS-RMSlike-DICER1 series occurring in the posterior fossa were highly similar to the supratentorial cases. The relation of those previously reported cerebellar rhabdomyosarcomas and SCS-RMSlike-DICER1 is therefore currently unresolved. Notably, in the course of this investigation, we also identified embryonal and alveolar rhabdomyosarcomas primarily manifesting in the CNS, which histologically and epigenetically matched with their peripheral counterparts. Thus, these cases were not further addressed here (data not shown).
A small number of extracranial sarcomas has previously been reported with DICER1 germline mutations [4] . DICER1 mutations appear to be frequent in embryonal rhabdomyosarcoma originating within the urogenital tract [4, 6, 7, 11] . Three studies employing whole exome sequencing on 102 fusion-negative rhabdomyosarcomas did not detect DICER1 mutations at all [13, 30, 31] . However, the number of analyzed tumors originating from the urogenital tract was relatively low. Interestingly, morphological features of rhabdomyosarcoma of the uterine cervix included cartilaginous nodules in nearly half of the cases (6/14), contrasting the single case (1/22) in our series of intracranial SCS-RMSlike-DICER1 [6] . However, one of the two uterine rhabdomyosarcomas in our series also exhibited cartilaginous nodules. In our series of 22 SCS-RMSlike-DICER1, germline DNA was available from five patients. Analysis of arrows in a, b, and e) . The predominant growth of these tumors was patternless (a-c). Some cases exhibited a prominent fascicular growth sometimes being reminiscent of a solitary fibrous tumor (d). Some cases showed, at least in some areas, a myxoid stroma matrix (e). Many cases showed signs for anaplasia with hyperchromatic enlarged and pleomorphic tumor cell nuclei (f) and/or atypical mitotic figures. The infiltration border was sometimes sharply demarcated, although small tumor cell islands infiltrated the adjacent brain parenchyma (g). Other cases showed a more diffuse infiltration pattern (h). Argyrophilic fibers stained by Tibor Pap silver impregnation (TP) were often thin (i). Scale bars equal 100 μm constitutional DNA revealed germline DICER1 mutations in two of these five patients. This may indicate a considerable proportion of all SCS-RMSlike-DICER1 having a hereditary background-a hypothesis that needs to be addressed in future studies. Germline mutations were accompanied by two findings: first, the type of germline mutations differed from that of somatic DICER1 mutations. Both germline mutations were of the nonsense type, resulting in a premature stop codon and protein truncation. Second, both patients with a DICER1 germline mutation carried an additional somatic missense mutation. The co-occurrence of two mutations in DICER1 was previously described in tumors arising in patients with DICER1 syndrome [12] . Four other patients in our series harbored two simultaneous DICER1 mutations. Three of these exhibited the combination of nonsense together with missense mutations, while one patient carried two missense mutations. Although we cannot provide proof for lack of constitutional DNA in these patients, we speculate on a hereditary background. This may indicate that a considerable number of SCS-RMSlike-DICER1 develop on a genetic predisposition background. Furthermore, copy number analysis revealed a loss of DICER1 in seven cases, indicating that such gene dosage effect may be an alternative way for a second DICER1 allele inactivation in SCS-RMSlike-DICER1, previously described in DICER1-related pineoblastomas [5] . The DICER1 mutational screening of the coding sequence including the exon-intron junction failed to detect any variant in a single SCS-RMSlike-DICER1. This case might harbor a deep intronic variant with pathogenic potential. Such variants have recently been described in DICER1-related tumors and often remain hidden by conventional NGS approaches [29, 35] .
The second most frequent gene affected by mutations in SCS-RMSlike-DICER1 was TP53, observed in 12/22 (55%) of the patients. Notably, the TP53 mutation frequency in SCS-RMSlike-DICER1 is much higher compared to previous findings in pediatric patients with rhabdomyosarcomas [21, 22, 30] . It is known that rhabdomyosarcoma may arise in the setting of Li-Fraumeni syndrome caused by germline mutations in TP53. Due to the lack of constitutional DNA, we could not determine the germline TP53 status in our cases. A very rare pediatric renal neoplasm referred to as anaplastic sarcoma of the kidney was first recognized in 2007 [36] . These tumors predominantly occur in female patients and exhibit histologic features reminiscent of pleuropulmonary blastomas. Interestingly, a recent study focusing on molecular alterations in these tumors revealed recurrent mutations in DICER1 and TP53 [38] . This may indicate a close relation between anaplastic sarcomas of the kidney and SCS-RMSlike-DICER1, although SCS-RMSlike-DICER1 seem to have an equal gender distribution.
Mutations in the MAP-kinase pathway occurred in 17/22 (77%) SCS-RMSlike-DICER1 (Fig. 4) . Most frequently affected was KRAS followed by NF1, NRAS, FGFR4, and EGFR. MAPK pathway gene mutations have also been observed in rhabdomyosarcoma without DICER1 mutations, albeit at a lower frequency [30] .
Four patients carried mutations in SUFU or SMO, both involved in the sonic hedgehog pathway. Recently a mouse model based on SMO-induced activated hedgehog pathway was shown to prompt transdifferentiation of non-myogenic endothelial progenitor cells by aberrant expression of myogenic specification factors resulting in fusion-negative rhabdomyosarcoma [9] . This may be of interest because Gorlin syndrome, caused by constitutional mutations in the sonic hedgehog pathway gene PTCH1, can be accompanied by embryonal rhabdomyosarcoma [17] .
It is yet unknown how SCS-RMSlike-DICER1-behave clinically. In our study, limited follow-up data does not allow for reliable conclusions regarding clinical behavior, however, preliminary data lead us to suspect an aggressive clinical course. Further investigations regarding biological and clinical aspects are necessary and warranted for a comprehensive understanding of this molecularly distinct sarcoma group.
In conclusion, we describe a set of predominantly pediatric intracranial spindle cell sarcomas exhibiting rhabdomyosarcoma-like features with a highly characteristic and diagnostic epigenetic and genetic profile. We propose this intriguing group to be called "spindle cell sarcoma with rhabdomyosarcoma-like features, DICER1 mutant".
